Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Interferon Alfa-2a vs Pegylated Interferon Alfa-2a for Induction Therapy in Chronic HCV
NCT00381953Phase 3Completed
- Sponsor
- Foundation for Liver Research
- Start
- Feb 2003
- Primary completion
- Apr 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised trial of peginterferon alfa-2a and interferon alfa-2a in hepatitis C (HCV) (3 arms), sponsored by Foundation for Liver Research. Primary endpoints: Pharmacokinetics by IFN assays at 4 weeks and Pharmacodynamics by HCV RNA suppression at 4 weeks. Started Feb 2003; status: completed.
02
Drugs
peginterferon alfa-2ainterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00381953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381953.